Please login to the form below

Not currently logged in
Email:
Password:

tardive dyskinesia

This page shows the latest tardive dyskinesia news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

Its KarXT molecule aims to avoid the safety issues that have given existing antipsychotic medicines a bad name, these include tardive dyskinesia, metabolic dysfunction, weight gain, glucose intolerance, sedation and others

Latest news

  • FDA clears Teva's tardive dyskinesia drug Austedo FDA clears Teva's tardive dyskinesia drug Austedo

    FDA clears Teva's tardive dyskinesia drug Austedo. The twice-daily drug will compete with Neurocrine Bioscience’s Ingrezza. ... April. Tardive dyskinesia, a neurological disorder characterised by repetitive involuntary movements such as grimacing,

  • Neurocrine bags FDA approval for first tardive dyskinesia drug Neurocrine bags FDA approval for first tardive dyskinesia drug

    Neurocrine bags FDA approval for first tardive dyskinesia drug. Ingrezza edges ahead of Teva’s rival drug Austedo. ... Neurocrine Biosciences has claimed the distinction of getting the first-ever FDA approval for a drug to treat tardive dyskinesia, a

  • FDA approves Teva's Huntington's disease drug at second attempt FDA approves Teva's Huntington's disease drug at second attempt

    tardive dyskinesia, a much larger movement disorder indication, which has no approved therapies in the US. ... It is estimated that around 35, 000 people have HD in the US, but the population with tardive dyskinesia, which often develops as a

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    FDA sets August review date for Teva's movement disorder drug. Could be first approved treatment for tardive dyskinesia. ... Patients with the movement disorder tardive dyskinesia (TD) could have a first approved treatment if the FDA clears Teva's SD-809

  • FDA turns down Teva's Huntington's disease drug FDA turns down Teva's Huntington's disease drug

    The metabolites issue is critical for Teva as it is also developing deutetrabenazine for other uses, notably tardive dyskinesia, a much larger indication which has no approved therapies in the US,

More from news
Approximately 7 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics